Bulletin from the annual general meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 2 June 2022 – The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor AB (publ) (“the Company”) on 2 June. The annual general meeting was carried out through advance voting (postal voting) only.

Adoption of income statement and balance sheet and discharge from liability

The AGM resolved to adopt the income statement for the financial year 2021 as well as the balance sheet and consolidated balance sheet as of 31 December 2021. The members of the board of directors and the managing director were discharged from liability for the financial year 2021.

Allocation of profit or loss

The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2021 and that the results of the company shall be carried forward.

Board of Directors and auditor

The AGM resolved, in accordance with the nomination committee’s proposal, on re-election of Fredrik Sjövall, Denis Angioletti, Ola Flink, Gunilla Lundmark and Otto Skolling as board members. Fredrik Sjövall was re-elected as the chairman of the Board of Directors. The AGM re-elected Öhrlings PricewaterhouseCoopers AB as auditor.

The AGM further resolved on remuneration to the Board of Directors in accordance with the nomination committee’s proposal. The AGM furthermore resolved in accordance with the nomination committee’s proposal, that remuneration to the auditor shall be paid in accordance with approved statement of costs.

Authorization to issue new shares, warrants or convertibles

The AGM resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, at one or several occasions and for the period up until the next annual general meeting, resolve to increase the company’s share capital by issuing new shares, warrants or convertibles. Such issue resolution may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions. The total number of shares that may be issued, or, in the event of an issue of warrants or convertibles, any additional shares after exercise of any warrant or conversion, pursuant to the authorization in this paragraph, shall be limited to 10 percent of the number of shares in the Company at the time of this general meeting.

The purpose of the proposed authorization is to increase the Company’s financial flexibility and the Board of Directors’ room for action. Should the Board of Directors resolve on a share issue with deviation from the shareholders’ pre-emption rights, the reason for this shall be to broaden the ownership structure, procure working capital, increase the liquidity of the share or acquire businesses, or enable the acquiring of capital for acquisitions.

Incentive programme

The AGM resolved, in accordance with the Board of Directors’ proposal, to adopt an incentive programme to employees consisting of employee stock options. In short, the incentive programme includes an issue of not more than 325 000 employee stock options. The AGM furthermore resolved on an issue of not more than 427 115 warrants in order to ensure delivery of shares to the participants and to hedge costs connected to the programme.   Each employee stock option entitles the holder to subscribe for shares in the Company during the time period of 1 May 2025 to 31 May 2025.


The information was provided for publication by Lipidor’s CEO on 2 June 2022 at 1.45pm CEST.

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0)72 50 70 369
Email: ola.holmlund@lipidor.se

Certified Adviser

Erik Penser Bank AB
Telephone: +46 (0)8 463 80 00
E-mail: certifiedadviser@penser.se

About Lipidor AB

Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.